Summary of Bliss scores and sensitivity to dinaciclib, navitoclax and combination treatment. Robert N. Booher Harold Hatch Brian M. Dolinski Thi Nguyen Lauren Harmonay Ali-Samer Al-Assaad Mark Ayers Michael Nebozhyn Andrey Loboda Heather A. Hirsch Theresa Zhang Bin Shi Carrie E. Merkel Minilik H. Angagaw Yaolin Wang Brian J. Long Xianlu Q. Lennon Nathan Miselis Vincenzo Pucci James W. Monahan Junghoon Lee Anna Georgieva Kondic Eun Kyung Im David Mauro Rebecca Blanchard Gary Gilliland Stephen E. Fawell Leigh Zawel Alwin G. Schuller Peter Strack 10.1371/journal.pone.0108371.t001 https://plos.figshare.com/articles/dataset/_Summary_of_Bliss_scores_and_sensitivity_to_dinaciclib_navitoclax_and_combination_treatment_/1196741 1<p>Synergy analysis after 18 hr treatment. vBliss: synergy (>0.1), additive (0.1–0.05). neutral (<0.05-0), antagonistic (<0).</p>2<p>Percent viability after 18 hour treatment with 100 nM dinaciclib, 1 µM navitoclax or the combination.</p>3<p>Information source. Cancer Cell Line Encyclopedia converted from log 2 to log10.</p><p>Summary of Bliss scores and sensitivity to dinaciclib, navitoclax and combination treatment.</p> 2014-10-07 03:18:02 MCL 1 antiapoptotic BCL 2 family member MCL 1 MCL 1 amplification BCL 2 family member inhibitors cdk mechanism dinaciclib antitumor response abt cell cycle progression